Focused On-demand Library for Sphingosine-1-phosphate lyase 1

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We employ our advanced, specialised process to create targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.







Alternative names:

Sphingosine-1-phosphate aldolase

Alternative UPACC:

O95470; B2RBD4; Q7Z732; Q9ULG8; Q9UN89


Sphingosine-1-phosphate lyase 1, alternatively known as Sphingosine-1-phosphate aldolase, plays a pivotal role in the metabolism of sphingolipids. It cleaves phosphorylated sphingoid bases into fatty aldehydes and phosphoethanolamine, crucial for lipid homeostasis and apoptosis. This enzyme is essential for maintaining global lipid balance in the liver, cholesterol regulation in fibroblasts, and modulates inflammatory responses and neuronal autophagy.

Therapeutic significance:

Nephrotic syndrome 14, a severe renal disorder leading to end-stage renal failure, is linked to mutations affecting Sphingosine-1-phosphate lyase 1. Understanding the role of this protein could open doors to potential therapeutic strategies, offering hope for patients suffering from this and possibly other related disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.